Antibodies directed to alphaVbeta6 and uses thereof

Details for Australian Patent Application No. 2007348941 (hide)

Owner MedImmune Limited

Inventors Rinkenberger, Julie; Alfred, Avril; Bedian, Vahe; Foltz, Ian; Barry, Simon Thomas

Agent Davies Collison Cave

Pub. Number AU-B-2007348941

PCT Pub. Number WO2008/112004

Priority 60/835,559 03.08.06 US

Filing date 2 August 2007

Wipo publication date 18 September 2008

Acceptance publication date 4 August 2011

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 5/00 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

Event Publications

19 February 2009 PCT application entered the National Phase

  PCT publication WO2008/112004 Priority application(s): WO2008/112004

14 April 2011 Assignment before Grant

  AstraZeneca AB The application has been assigned to MedImmune Limited 2008

4 August 2011 Application Accepted

  Published as AU-B-2007348941

1 December 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007348944-Immunoreactive glycoprotein GP19 of Ehrlichia canis

2007348940-Targeted binding agents directed to PDGFR-alpha and uses thereof